Replies to post #90918 on Biotech Values

[rkrw]

Obviously NVS can't launch on Copaxone without FDA approval. I'm sure a lot of brand companies would love to see teva get a dose of their own medicine.

[Biopharm investor]

flatlander_60048

If NVS was to prevail in litigation, how would damages be calculated? I believe the law allows for treble damages (are these calculated based on sales or profits?

Damages would be calculated on NVS' lost profits.

I think the possibility of treble damages in this case would be relatively low.